Spyre Therapeutics (SYRE) – Analysts’ Recent Ratings Updates

A number of firms have modified their ratings and price targets on shares of Spyre Therapeutics (NASDAQ: SYRE) recently:

• 9/9/2026 – Spyre Therapeutics had its “outperform” rating reaffirmed by Wedbush. They now have a $123.00 price target on the stock.
• 9/8/2026 – Spyre Therapeutics had its “buy” rating reaffirmed by BTIG Research. They now have a $121.00 price target on the stock.
• 9/1/2026 – Spyre Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 8/26/2026 – Spyre Therapeutics had its price target lowered by Deutsche Bank Aktiengesellschaft from $135.00 to $127.00. They now have a “buy” rating on the stock.
• 8/26/2026 – Spyre Therapeutics had its price target lowered by Wedbush from $130.00 to $123.00. They now have an “outperform” rating on the stock.
• 8/26/2026 – Spyre Therapeutics had its price target lowered by BTIG Research from $132.00 to $121.00. They now have a “buy” rating on the stock.
• 8/16/2026 – Spyre Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 8/11/2026 – Spyre Therapeutics had its price target raised by BTIG Research from $112.00 to $132.00. They now have a “buy” rating on the stock.
• 8/8/2026 – Spyre Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
• 8/5/2026 – Spyre Therapeutics was given a new $120.00 price target by Robert W. Baird.
• 8/5/2026 – Spyre Therapeutics had its price target raised by Wells Fargo & Company from $90.00 to $115.00. They now have an “overweight” rating on the stock.
• 8/5/2026 – Spyre Therapeutics had its price target raised by Wedbush from $100.00 to $130.00. They now have an “outperform” rating on the stock.
• 8/5/2026 – Spyre Therapeutics had its price target raised by Guggenheim from $115.00 to $130.00. They now have a “buy” rating on the stock.
• 7/28/2026 – Spyre Therapeutics was downgraded by Wolfe Research from “outperform” to “peer perform”.
• 7/13/2026 – Spyre Therapeutics had its price target raised by Mizuho from $84.00 to $120.00. They now have an “outperform” rating on the stock.

Insider Buying and Selling at Spyre Therapeutics

In related news, Director Jeffrey W. Albers sold 18,000 shares of the company’s stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $104.55, for a total transaction of $1,881,900.00. Following the completion of the transaction, the director owned 9,360 shares in the company, valued at $978,588. This represents a 65.79% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Scott L. Burrows sold 18,232 shares of the firm’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $89.35, for a total value of $1,629,029.20. Following the completion of the sale, the chief financial officer directly owned 79,762 shares of the company’s stock, valued at $7,126,734.70. The trade was a 18.61% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 180,465 shares of company stock worth $16,638,714 over the last three months. 15.69% of the stock is owned by corporate insiders.

Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on developing next-generation antibody therapies for inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis. The company’s approach is designed to address significant treatment needs in chronic immune-mediated conditions through therapies with potentially improved efficacy, durability and dosing convenience.

Spyre’s pipeline includes investigational antibody programs targeting biological pathways associated with IBD, including interleukin-23 (IL-23), TL1A and integrin-mediated immune activity.